SEATTLE, WASHINGTON — Sound Pharmaceuticals has presented a new analysis of Phase 3 clinical trial data showing significant improvements in hearing thresholds and speech understanding among patients with Ménière’s disease treated with its investigational oral drug, SPI-1005....
Continue reading at Hearing Health Matters
✦ The floor
Discussion
Signed responses from readers of the wire.
No actionable change — results are from a company-presented Phase 3 analysis; peer-reviewed publication and regulatory review are needed before any practice change is warranted.
If independently confirmed, SPI-1005 could become the first approved oral pharmacotherapy to meaningfully improve hearing outcomes in Ménière's disease, an area with very limited treatment options.
- 01SPI-1005 is an investigational oral drug targeting hearing loss in Ménière's disease (inner-ear disorder causing hearing loss and dizziness).
- 02Phase 3 analysis showed statistically significant improvements in hearing thresholds (the softest sounds a person can detect) and speech understanding.
- 03Results were presented by the manufacturer, Sound Pharmaceuticals — not yet published in a peer-reviewed journal.
- 04Ménière's disease currently has few proven treatments targeting hearing outcomes.
- 05Full peer review and potential regulatory submission are the critical next steps.
SPI-1005 significantly improved hearing thresholds in patients with Ménière's disease in a Phase 3 analysis.
press releasepartially supportedSPI-1005 significantly improved speech understanding in patients with Ménière's disease in a Phase 3 analysis.
press releasepartially supported- Publication type
- clinical_trial
- Evidence level
- 1b
- Population
- Patients with Ménière's disease experiencing hearing loss
- Intervention
- SPI-1005 oral investigational drug (ebselen)
Primary outcomes
Hearing threshold improvement (pure-tone audiometry); Speech understanding scores